Atacicept

Vera Therapeutics

Dual BAFF/APRIL inhibitor. ORIGIN-3 Phase 3 met primary endpoint (46% proteinuria reduction vs placebo, p<0.0001). BLA filed Nov 2025. FDA decision expected 2026. First dual BAFF/APRIL inhibitor in IgAN.

Linked Studies

Also Known As